Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes

BACKGROUND Several glitazones (PPARγ agonists) and glitazars (dual PPARα/γ agonists) have been developed to treat hyperglycemia and, simultaneously, hyperglycemia and dyslipidemia, respectively. However, most have caused idiosyncratic hepatic or extrahepatic toxicities through mechanisms that remain largely unknown. Since the liver plays a key role in lipid metabolism, we analyzed changes in gene expression profiles induced by these two types of PPAR agonists in human hepatocytes. METHODOLOGY/PRINCIPAL FINDINGS Primary human hepatocytes and the well-differentiated human hepatoma HepaRG cells were exposed to different concentrations of two PPARγ (troglitazone and rosiglitazone) and two PPARα/γ (muraglitazar and tesaglitazar) agonists for 24 h and their transcriptomes were analyzed using human pangenomic Agilent microarrays. Principal Component Analysis, hierarchical clustering and Ingenuity Pathway Analysis® revealed large inter-individual variability in the response of the human hepatocyte populations to the different compounds. Many genes involved in lipid, carbohydrate, xenobiotic and cholesterol metabolism, as well as inflammation and immunity, were regulated by both PPARγ and PPARα/γ agonists in at least a number of human hepatocyte populations and/or HepaRG cells. Only a few genes were selectively deregulated by glitazars when compared to glitazones, indicating that PPARγ and PPARα/γ agonists share most of their target genes. Moreover, some target genes thought to be regulated only in mouse or to be expressed in Kupffer cells were also found to be responsive in human hepatocytes and HepaRG cells. CONCLUSIONS/SIGNIFICANCE This first comprehensive analysis of gene regulation by PPARγ and PPARα/γ agonists favor the conclusion that glitazones and glitazars share most of their target genes and induce large differential changes in gene profiles in human hepatocytes depending on hepatocyte donor, the compound class and/or individual compound, thereby supporting the occurrence of idiosyncratic toxicity in some patients.

[1]  L. Tecott,et al.  Up-Regulation of Peroxisome Proliferator-Activated Receptors (PPAR-α) and PPAR-γ Messenger Ribonucleic Acid Expression in the Liver in Murine Obesity: Troglitazone Induces Expression of PPAR-γ-Responsive Adipose Tissue-Specific Genes in the Liver of Obese Diabetic Mice* * This work was supported by , 2000, Endocrinology.

[2]  B. Schreiber,et al.  PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes , 2005 .

[3]  Arnaud Pillon,et al.  Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands , 2005 .

[4]  A. Sato,et al.  Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. , 2002, Toxicology.

[5]  C. Chesné,et al.  Comparison of the induction of hepatic peroxisome proliferation by the herbicide oxadiazon in vivo in rats, mice, and dogs and in vitro in rat and human hepatocytes. , 1996, Toxicology and applied pharmacology.

[6]  Manabu T. Nakamura,et al.  Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PPARalpha in nonproliferating species. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[7]  T. Olivecrona,et al.  Lipoprotein lipase in lungs, spleen, and liver: synthesis and distribution. , 1991, Journal of lipid research.

[8]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[9]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  James E Klaunig,et al.  PPARalpha agonist-induced rodent tumors: modes of action and human relevance. , 2003, Critical reviews in toxicology.

[11]  F. Ferré,et al.  Gene Expression Analysis of Troglitazone Reveals Its Impact on Multiple Pathways in Cell Culture: A Case for In Vitro Platforms Combined with Gene Expression Analysis for Early (Idiosyncratic) Toxicity Screening , 2006, International journal of toxicology.

[12]  Rita Ouellet-Hellstrom,et al.  Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. , 2010, JAMA.

[13]  M. Saboorian,et al.  Hepatic injury due to troglitazone. , 2000, Digestive diseases and sciences.

[14]  B. Staels,et al.  PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome , 2006 .

[15]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[16]  D. Moller,et al.  Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. , 2000, Molecular pharmacology.

[17]  S. O. Mueller,et al.  Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  M. Anwer.  Cellular regulation of hepatic bile acid transport in health and cholestasis , 2004, Hepatology.

[19]  Béatrice Desvergne,et al.  From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.

[20]  S. Ledoux,et al.  Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. , 2009, Toxicology and applied pharmacology.

[21]  O. Fardel,et al.  FUNCTIONAL EXPRESSION OF SINUSOIDAL DRUG TRANSPORTERS IN PRIMARY HUMAN AND RAT HEPATOCYTES , 2005, Drug Metabolism and Disposition.

[22]  G. Schroth,et al.  Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR γ agonists on rat primary hepatocytes and human HepG2 cells , 2006, Molecular Diversity.

[23]  H. Yamazaki,et al.  Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. , 2001, Life sciences.

[24]  F. Gonzalez,et al.  PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.

[25]  J. Sahi,et al.  Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[26]  Weida Tong,et al.  Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists , 2006, BMC Bioinformatics.

[27]  U. Boelsterli,et al.  Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. , 2000, Biochemical pharmacology.

[28]  G. Williams,et al.  Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. , 1998, Toxicology and applied pharmacology.

[29]  Michael Müller,et al.  Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.

[30]  D. Feinstein,et al.  Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? , 2005, Biochemical pharmacology.

[31]  Samuel M. Cohen,et al.  Rodent Carcinogenicity Profile of the Antidiabetic Dual PPAR α and γ Agonist Muraglitazar , 2007 .

[32]  B. Staels,et al.  Therapeutic roles of peroxisome proliferator-activated receptor agonists. , 2005, Diabetes.

[33]  F. Gonzalez.  The peroxisome proliferator-activated receptor α (PPARα): role in hepatocarcinogenesis , 2002, Molecular and Cellular Endocrinology.

[34]  D. Jaeck,et al.  Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human hepatocyte cultures. , 1999, Toxicology and applied pharmacology.

[35]  F. Staedtler,et al.  Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. , 2003, Toxicology and applied pharmacology.

[36]  Valérie Fessard,et al.  Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies , 2008, Drug Metabolism and Disposition.

[37]  Michael Müller,et al.  Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human , 2009, PloS one.

[38]  W. Roesler,et al.  Troglitazone Induces Expression of PPARγ in Liver , 1999 .

[39]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[40]  W. Humphreys,et al.  Comparative Metabolism of Radiolabeled Muraglitazar in Animals and Humans by Quantitative and Qualitative Metabolite Profiling , 2007, Drug Metabolism and Disposition.

[41]  A. Guillouzo,et al.  Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver , 2010, PPAR research.

[42]  L. Fuentes,et al.  Inflammatory Mediators and Insulin Resistance in Obesity: Role of Nuclear Receptor Signaling in Macrophages , 2010, Mediators of inflammation.

[43]  S. Kersten,et al.  Peroxisome proliferator-activated receptor α target genes , 2004, Cellular and Molecular Life Sciences CMLS.

[44]  W. Isley.  Hepatotoxicity of thiazolidinediones , 2003, Diabetes, obesity & metabolism.

[45]  J. Peters,et al.  Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  T. Billiar,et al.  Hepatocytes express functional NOD1 and NOD2 receptors: a role for NOD1 in hepatocyte CC and CXC chemokine production. , 2010, Journal of hepatology.

[47]  Atsushi Ono,et al.  Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. , 2006, The Journal of toxicological sciences.

[48]  B. Drénou,et al.  Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor , 2007, Hepatology.

[49]  A. Guillouzo,et al.  Running title page Running title : Functional stability of CYP P 450 enzymes in HepaRG cells , 2009 .

[50]  F. Gonzalez,et al.  Adipocyte-specific Gene Expression and Adipogenic Steatosis in the Mouse Liver Due to Peroxisome Proliferator-activated Receptor γ1 (PPARγ1) Overexpression* , 2003, The Journal of Biological Chemistry.

[51]  A. Guillouzo,et al.  Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. , 2009, Toxicology and applied pharmacology.

[52]  Christina Magkoufopoulou,et al.  Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[53]  F. Gonzalez,et al.  The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[54]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[55]  Margaret S. Wu,et al.  Evidence for Peroxisome Proliferator-Activated Receptor (PPAR)α-Independent Peroxisome Proliferation: Effects of PPARγ/δ-Specific Agonists in PPARα-Null Mice , 2000 .

[56]  S. O. Mueller,et al.  Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. , 2009, Chemico-biological interactions.

[57]  L. Lesko,et al.  Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[58]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[59]  David Y. Lai,et al.  PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .

[60]  Weiqi Wang,et al.  Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. , 2005, Journal of medicinal chemistry.

[61]  Ann K. Miller,et al.  Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[62]  A. Guillouzo,et al.  Liver cell models in in vitro toxicology. , 1998, Environmental health perspectives.

[63]  E. Randinitis,et al.  Clinical Pharmacokinetics of Troglitazone , 1999, Clinical pharmacokinetics.

[64]  U. Andersson,et al.  Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[65]  M. Chung,et al.  Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury. , 2008, Toxicology and applied pharmacology.

[66]  Michael Müller,et al.  Kupffer cells promote hepatic steatosis via interleukin‐1β–dependent suppression of peroxisome proliferator‐activated receptor α activity , 2010, Hepatology.

[67]  A. Guillouzo,et al.  High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. , 1982, Cell biology international reports.

[68]  J. Rothberg,et al.  The characterization of PPAR alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling. , 2001, Functional & integrative genomics.

[69]  U. Andersson,et al.  Tesaglitazar, a PPARα/γ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats , 2007 .

[70]  D. Hum,et al.  Safety issues and prospects for future generations of PPAR modulators. , 2007, Biochimica et biophysica acta.

[71]  B. Hamrén,et al.  Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[72]  M. Dominick,et al.  Nonclinical Safety Evaluation of Muraglitazar, a Novel PPARα/γ Agonist , 2007 .

[73]  F. Gonzalez,et al.  The PPARα-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARα , 2008 .

[74]  Neal F Cariello,et al.  Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[75]  M. Harada,et al.  Hydrogen peroxide overproduction in megamitochondria of troglitazone‐treated human hepatocytes , 2003, Hepatology.

[76]  E. Topol,et al.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.

[77]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[78]  B. Staels,et al.  PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. , 2006, Current opinion in pharmacology.

[79]  J. Rothberg,et al.  The characterization of PPARα ligand drug action in an in vivo model by comprehensive differential gene expression profiling , 2001, Functional & Integrative Genomics.

[80]  Martyn T. Smith,et al.  Mechanisms of troglitazone hepatotoxicity. , 2003, Chemical research in toxicology.

[81]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[82]  Katy O Goyak,et al.  Expression profiling of interindividual variability following xenobiotic exposures in primary human hepatocyte cultures. , 2008, Toxicology and applied pharmacology.

[83]  Tommy B. Andersson,et al.  HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans , 2008, Drug Metabolism And Disposition.